Figure 3.

Topical administration of NPD1 started during clinical phase (day 6 pi) decreases SK severity. C57BL/6 mice infected with 2 × 10⁴ PFU of HSV-1 RE were given NPD1 topically twice daily starting from day 6 until day 12 pi. The disease severity was examined on different days after infection. (A–C) Disease progression (until day 15 pi), SK lesion severity, and angiogenesis at day 15 pi are shown. The level of significance was determined by Student's t-test (unpaired). Error bars represent mean ± SEM. Experiments were repeated at least three times, n = 16–18 mice/group as indicated in the scatter plots. (D, E) Mice were terminated at day 15 pi and eyes were processed for immunohistochemical analysis. Hematoxylin and eosin (H&E) staining was performed on 6-μm sections. The Figure shows the pictures of the sections taken at ×20 magnification. (F) Disease progression until day 21 pi. **P ≤ 0.01.